Sunday, March 04, 2018 4:26:43 PM
KIT-302 targets osteoarthritic patients currently treated with NSAIDs
(celecoxib as well as others) who also suffer from existing or newly diagnosed hypertension: if black box removed it certainly reduces concerns related to NSAIDs side effects (cardiovascular and renal ones) and improves patient compliance.
The phase III and the phase III/IV documented that unlike adding an NSAIDs to any other type of HTN drug, KIT-302 (Consensi) is safe and effective and no toxic.
EnricoMania
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM